Top

Published in:

01-11-2003 | Review Article

Improving Health-Related Quality of Life in Gastro-Oesophageal Reflux Disease

Authors: Michael J. Shaw, Joseph A. Crawley

Published in: Drugs | Issue 21/2003

Abstract

Gastro-oesophageal reflux disease (GORD) is a common, chronic disorder that can progress to erosive or ulcerative oesophagitis and other complications. Uncomplicated GORD can be defined using criteria that combine symptom assessment and the impact of symptoms on well being or quality of life. The extent of impairment of health-related quality of life (HRQL) in GORD patients has been evaluated using generic HRQL questionnaires, GORD-specific quality of life questionnaires or a combination of the two types of instruments. The impact of GORD on HRQL in affected individuals is proportional to the frequency and severity of heartburn, and is greater than that associated with many other chronic diseases. In the treatment of GORD, the goal should be complete symptom resolution as this has been shown to be associated with a clinically significant improvement in HRQL. Both drug treatment and surgical intervention have been successful in improving HRQL of patients with GORD when complete symptom resolution can be attained

National Digestive Diseases Information Clearinghouse. Gastroesophageal reflux disease (hiatal hernia and heartburn) [online]. Available from URL: http://www.niddk.nih.gov/health/digest/pubs/heartbrn/heartbrn.htm [Accessed 2000 Jun 27]

Enck P, Dubois D, Marquis P. Quality of life in patients with upper gastrointestinal symptoms: results from the Domestic/ International Gastroenterology Surveillance Study (DIGEST). Scand J Gastroenterol 1999; 34 Suppl. 231: 48–54CrossRef

Younes Z, Johnson DA. Diagnostic evaluation in gastroesophageal reflux disease. Gastroenterol Clin North Am 1999; 28: 809–30PubMedCrossRef

Katz PO. Treatment of gastroesophageal reflux disease: use of algorithms to aid in management. Am J Gastroenterol 1999; 94: S3–S10PubMedCrossRef

LockeIII GR, Talley NJ, Fett SL, et al. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 1997; 112: 1448–56PubMedCrossRef

Fass R, Fennerty MB, Vakil N. Nonerosive reflux diseasecurrent concepts and dilemmas. Am J Gastroenterol 2001; 96: 303–14PubMed

Johanson J, Hwang C, Roach A. Prevalence of erosive esophagitis (EE) in patients with gastroesophageal reflux disease (GERD) [abstract]. Gastroenterology 2001; 120: A1219

Chiba N. Proton pump inhibitors in acute healing and maintenance of erosive or worse esophagitis: a systematic overview. Can J Gastroenterol 1997; 11 Suppl. B: 66B–73BPubMed

Ben Rejeb M, Bouche O, Zeitoun P. Study of 47 consecutive patients with peptic esophageal stricture compared with 3880 cases of reflux esophagitis. Dig Dis Sci 1992; 37(5): 733–6PubMedCrossRef

10.

Carlsson R, Dent J, Watts R, et al. Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group. Eur J Gastroenterol Hepatol 1998; 10: 119–24PubMedCrossRef

11.

Dent J, Brun J, Fendrick A, et al. An evidence-based appraisal of reflux disease management: the Genval Workshop report. Gut 1999; 44: S1–S16CrossRef

12.

Revicki DA, Crawley JA, Zodet MW, et al. Complete resolution of heartburn symptoms and health-related quality of life in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1999; 13: 1621–30PubMedCrossRef

13.

Silvis SE, Farahmand M, Johnson JA, et al. A randomized blinded comparison of omeprazole and ranitidine in the treatment of chronic esophageal stricture secondary to acid peptic esophagitis. Gastrointest Endosc 1996; 43: 216–21PubMedCrossRef

14.

Kahrilas PJ, Falk GW, Johnson DA, et al. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. The Esomeprazole Study Investigators. Aliment Pharmacol Ther 2000; 14: 1249–58PubMedCrossRef

15.

Fass R, Ofman JJ, Sampliner RE, et al. The omeprazole test is as sensitive as 24h oesophageal pH monitoring in diagnosing gastro-oesophageal reflux disease in symptomatic patients with erosive oesophagitis. Aliment Pharmacol Ther 2000; 14: 389–96PubMedCrossRef

16.

Sontag SJ. Gastroesophageal reflux and asthma. Am J Med 1997; 103: 84S–90SPubMedCrossRef

17.

El-Serag HB, Sonnenberg A. Comorbid occurrence of laryngeal or pulmonary disease with esophagitis in United States military veterans. Gastroenterology 1997; 113: 755–60PubMedCrossRef

18.

DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. The Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol 1999; 94: 1434–42PubMedCrossRef

19.

Dent J, Jones R, Kahrilas P, et al. Management of gastrooesophageal reflux disease in general practice. BMJ 2001; 322: 344–7PubMedCrossRef

20.

Higginson IJ, Carr AJ. Measuring quality of life: using quality of life measures in the clinical setting. BMJ 2001; 322: 1297–300PubMedCrossRef

21.

Moyer CA, Fendrick AM. Measuring health-related quality of life in patients with upper gastrointestinal disease. Dig Dis 1998; 16: 315–24PubMedCrossRef

22.

Yacavone RF, LockeIII GR, Provenzale DT, et al. Quality of life measurement in gastroenterology: what is available? Am J Gastroenterol 2001; 96: 285–97PubMedCrossRef

23.

Colwell HH, Mathias SD, Pasta DJ, et al. Development of a health-related quality-of-life questionnaire for individuals with gastroesophageal reflux disease: a validation study. Dig Dis Sci 1999; 44: 1376–83PubMedCrossRef

24.

Wiklund IK, Junghard O, Grace E, et al. Quality of life in reflux and dyspepsia patients: psychometric documentation of a new disease-specific questionnaire (QOLRAD). Eur J Surg Suppl 1998; 583: 41–9

25.

Velanovich V, Karmy-Jones R. Measuring gastroesophageal reflux disease: relationship between the Health-Related Quality of Life score and physiologic parameters. Am Surg 1998; 64: 649–53PubMed

26.

Brazier JE, Harper R, Jones NM, et al. Validating the SF-36 health survey questionnaire: new outcome measure for primary care. BMJ 1992; 305: 160–4PubMedCrossRef

27.

Havelund T, Lind T, Wiklund I, et al. Quality of life in patients with heartburn but without esophagitis: effects of treatment with omeprazole. Am J Gastroenterol 1999; 94: 1782–9PubMedCrossRef

28.

Revicki DA, Sorensen S, Maton PN, et al. Health-related quality of life outcomes of omeprazole versus ranitidine in poorly responsive symptomatic gastroesophageal reflux disease. Dig Dis 1998; 16: 284–91PubMedCrossRef

29.

Mathias SD, Castell DO, Elkin EP, et al. Health-related quality of life of patients with acute erosive reflux esophagitis. Dig Dis Sci 1996; 41: 2123–9PubMedCrossRef

30.

McDougall NI, Johnston BT, Kee F, et al. Natural history of reflux oesophagitis: a 10 year follow up of its effect on patient symptomatology and quality of life. Gut 1996; 38: 481–6PubMedCrossRef

31.

Revicki DA, Wood M, Wiklund I, et al. Reliability and validity of the Gastrointestinal Symptom Rating Scale in patients with gastroesophageal reflux disease. Qual Life Res 1998; 7: 75–83PubMedCrossRef

32.

Revicki DA, Wood M, Maton PN, et al. The impact of gastroesophageal reflux disease on health-related quality of life. Am J Med 1998; 104: 252–8PubMedCrossRef

33.

Dimenäs E. Methodological aspects of evaluation of quality of life in upper gastrointestinal diseases. Scand J Gastroenterol Suppl 1993; 199: 18–21CrossRef

34.

Stewart AL, Greenfield S, Hays RD, et al. Functional status and well-being of patients with chronic conditions: results from the Medical Outcomes Study. JAMA 1989; 262: 907–13PubMedCrossRef

35.

Reilly JP. Safety profile of the proton-pump inhibitors. Am J Health Syst Pharm 1999; 56: S11–7PubMed

36.

Sabesin SM. Safety issues relating to long-term treatment with histamine H2-receptor antagonists. Aliment Pharmacol Ther 1993; 7: 35–40PubMedCrossRef

37.

McDougall NI, Collins JS, McFarland RJ, et al. The effect of treating reflux oesophagitis with omeprazole on quality of life. Eur J Gastroenterol Hepatol 1998; 10: 459–64PubMedCrossRef

38.

Chal KL, Stacey JH, Sacks GE. The effect of ranitidine on symptom relief and quality of life of patients with gastrooesophageal reflux disease. Br J Clin Pract 1995; 49: 73–7PubMed

39.

Green J, Venables T, Bate C. Omeprazole produces a greater improvement in quality of life than placebo, antacid-alginate, ranitidine, cimetidine or cisapride in patients with gastrooesophageal reflux disease. Br J Med Econ 1997; 11: 121–31

40.

Goldberg D, Bridges K, Duncan-Jones P, et al. Detecting anxiety and depression in general medical settings. BMJ 1988; 297: 897–9PubMedCrossRef

41.

Rush DR, Stelmach WJ, Young TL, et al. Clinical effectiveness and quality of life with ranitidine vs placebo in gastroesophageal reflux disease patients: a clinical experience network (CEN) study. J Fam Pract 1995; 41: 126–36PubMed

42.

Wiklund I, Bardhan KD, Muller-Lissner S, et al. Quality of life during acute and intermittent treatment of gastro-oesophageal reflux disease with omeprazole compared with ranitidine: results from a multicentre clinical trial. The European Study Group. Ital J Gastroenterol Hepatol 1998; 30: 19–27

43.

Geraedts A, de Groot G, Hazenberg B. Omeprazole therapy improves quality of life in patients with reflux oesophagitis [abstract]. Gastroenterology 1994; 106: A80

44.

Festen HP, Schenk E, Tan G, et al. Omeprazole versus highdose ranitidine in mild gastroesophageal reflux disease: shortand long-term treatment: the Dutch Reflux Study Group. Am J Gastroenterol 1999; 94: 931–6PubMedCrossRef

45.

Goves J, Oldring JK, Kerr D, et al. First line treatment with omeprazole provides an effective and superior alternative strategy in the management of dyspepsia compared to antacid/ alginate liquid: a multicentre study in general practice. Aliment Pharmacol Ther 1998; 12: 147–57PubMedCrossRef

46.

Rohss K, Hasselgren G, Hedenstrom H. Effect of esomeprazole 40mg vs omeprazole 40mg on 24-hour intragastric pH in patients with symptoms of gastroesophageal reflux disease. Dig Dis Sci 2002; 47: 954–8PubMedCrossRef

47.

Hagen JA, Peters JH. Minimally invasive approaches to antireflux surgery. Semin Thorac Cardiovasc Surg 2000; 12: 157–72PubMed

48.

Spechler SJ, Lee E, Ahnen D, et al. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial. JAMA 2001; 285: 2331–8PubMedCrossRef

49.

Lundell L, Miettinen P, Myrvold HE, et al. Continued (5-year) followup of a randomized clinical study comparing antireflux surgery and omeprazole in gastroesophageal reflux disease. J Am Coll Surg 2001; 192: 172–81PubMedCrossRef

Title: Improving Health-Related Quality of Life in Gastro-Oesophageal Reflux Disease
Authors: Michael J. Shaw
Joseph A. Crawley
Publication date: 01-11-2003
Publisher: Springer International Publishing
Published in: Drugs / Issue 21/2003
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI: https://doi.org/10.2165/00003495-200363210-00003

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Improving Health-Related Quality of Life in Gastro-Oesophageal Reflux Disease

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 21/2003

Bemiparin

Oral Fludarabine

Lacidipine

Oral Fludarabine

Oral Fludarabine

Newer Formulations of the Triptans